National Health Investors (NHI)
(Delayed Data from NYSE)
$63.40 USD
+0.34 (0.54%)
Updated May 1, 2024 04:00 PM ET
After-Market: $63.45 +0.05 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NHI 63.40 +0.34(0.54%)
Will NHI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NHI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NHI
Strength Seen in Innovative Industrial Properties (IIPR): Can Its 4.8% Jump Turn into More Strength?
Industrial Logistics Properties Trust (ILPT) Tops Q1 FFO and Revenue Estimates
NHI: What are Zacks experts saying now?
Zacks Private Portfolio Services
National Health Investors (NHI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
National Health Investors (NHI) Q4 FFO Top Estimates
Four Corners Property Trust (FCPT) Q4 FFO Surpass Estimates
Other News for NHI
What's Driving Medical Properties Trust Inc's Surprising 42% Stock Rally?
NHI Crosses Above Average Analyst Target
Optimistic Outlook for National Health Investors Fueled by Strong Balance Sheet and Growth Potential
Land & Buildings Issues Letter to Shareholders of National Health Investors Announcing its Intention to Vote Against Two Directors at 2024 Annual Meeting
Activist Land & Buildings plans to vote against two National Health Investors directors